Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Deals

Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV

Fineline Cube Aug 8, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...

Company Drug

Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME

Fineline Cube Aug 8, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Drug

Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma

Fineline Cube Aug 8, 2022

Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has...

Company Legal / IP R&D

Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief

Fineline Cube Aug 8, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...

Hospital Policy / Regulatory

NHC Issues Notification on Medication Safety Management and Rational Drug Use

Fineline Cube Aug 8, 2022

The National Healthcare Commission (NHC) has released a notification focusing on medication safety management and...

Company Deals

Ningbo Health Gene Raises Hundreds of Millions in Series C Financing

Fineline Cube Aug 8, 2022

Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised...

Company Medical Device

Intuitive Surgical-Fosun JV Breaks Ground on Shanghai Medical Robot Base

Fineline Cube Aug 8, 2022

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture (JV) between China-based Shanghai Fosun...

Company

Bayer AG’s Q2 2022 Results Show Global Sales Growth Amid China VBP Pressures

Fineline Cube Aug 8, 2022

Germany-based pharmaceutical giant Bayer AG (VIE: BAYN) released its Q2 2022 financial report, revealing a...

Company Deals

Intellective Biologics Raises Over RMB500m in Series C Financing Round

Fineline Cube Aug 5, 2022

China-based macromolecule-focused Contract Development and Manufacturing Organization (CDMO) Intellective Biologics (Suzhou) Co., Ltd has reportedly...

Company Deals

MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development

Fineline Cube Aug 5, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of...

Company Deals

invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19

Fineline Cube Aug 5, 2022

invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that...

Company Drug

Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China

Fineline Cube Aug 5, 2022

US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...

Company

BeiGene’s Q2 2022 Revenues Surge 120%, Brukinsa Sales Triple

Fineline Cube Aug 5, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording...

Company Deals

Innovent Biologics and Sanofi Announce License Deal for Drug Development in China

Fineline Cube Aug 5, 2022

China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...

Company

Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge

Fineline Cube Aug 5, 2022

US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...

Company

Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip

Fineline Cube Aug 5, 2022

Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...

Company Deals

Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration

Fineline Cube Aug 5, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...

Company Drug

Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment

Fineline Cube Aug 5, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and...

Company Drug

CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study

Fineline Cube Aug 5, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for...

Company Deals

HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization

Fineline Cube Aug 5, 2022

China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...

Posts pagination

1 … 664 665 666 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.